Patents by Inventor Aurora PUJOL ONOFRE

Aurora PUJOL ONOFRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NRF2 activators for the prevention and/or treatment of axonal degeneration
    Patent number: 11382889
    Abstract: Therapeutic solutions for axonal degeneration include use of NRF2 activators in prevention and/or treatment of axonal degeneration. A method of prevention and/or treating axonal degeneration includes administering a therapeutically effective amount of a NRF2 activator selected from a GSK3 inhibitor or the compound of formula (I): wherein R1 and R2, which may be the same or different, independently represent H, a linear, branched wherein R1 and R2, which may be the same or different, independently represent a linear, branched or cyclic, saturated or unsaturated C1-6 alkyl radical, a pharmaceutical salt thereof or a metabolite or precursor of the dimethyl fumarate to a patient in need of the treatment.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: July 12, 2022
    Assignees: INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
    Inventors: Aurora Pujol Onofre, Stéphane Fourcade
  • NRF2 ACTIVATORS FOR THE PREVENTION AND/OR TREATMENT OF AXONAL DEGENERATION
    Publication number: 20190321322
    Abstract: Therapeutic solutions for axonal degeneration include use of NRF2 activators in prevention and/or treatment of axonal degeneration. A method of prevention and/or treating axonal degeneration includes administering a therapeutically effective amount of a NRF2 activator selected from a GSK3 inhibitor or the compound of formula (I): wherein R1 and R2, which may be the same or different, independently represent H, a linear, branched wherein R1 and R2, which may be the same or different, independently represent a linear, branched or cyclic, saturated or unsaturated C1-6 alkyl radical, a pharmaceutical salt thereof or a metabolite or precursor of the dimethyl fumarate to a patient in need of the treatment.
    Type: Application
    Filed: April 19, 2018
    Publication date: October 24, 2019
    Inventors: Aurora PUJOL ONOFRE, Stéphane FOURCADE
  • METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND FOR THE TREATMENT OF ADRENOLEUKODYSTROPHY
    Publication number: 20190010535
    Abstract: The present invention is directed to a diagnostic method for adrenoleukodystrophy in a subject based on the determination of the levels of different markers. The invention also provides a method for monitoring the progression of an adrenoleukodystrophy, a method for monitoring the effect of an adrenoleukodystrophy therapy and fingolimod, an analogue, metabolite or derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of anadrenoleukodystrophy.
    Type: Application
    Filed: July 14, 2016
    Publication date: January 10, 2019
    Inventors: Aurora PUJOL ONOFRE, Manuel PORTERO OTIN, Reinaldo PAMPLONA GRAS, Adolfo Jose LOPEZ DE MUNAIN ARREGI, Mariona JOVE FONT, Stephane FOURCADE
  • Specific mTOR inhibitors in the treatment of X-linked adrenoleukodystrophy
    Patent number: 10071063
    Abstract: The invention relates to novel uses of specific mTOR inhibitors as a medicament, in particular for the treatment of X-linked adrenoleukodystrophy (X-ALD). The invention also relates to a method for identifying a compound potentially useful for the treatment and/or prevention of X-ALD.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: September 11, 2018
    Assignees: FUNDACION DE LA COMUNIDAD VALENCIANA ENTRO DE INVESTIGACION PRINCIPE FELIPE, INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL), CENTRO DE INVESTIGACION BIOMEDICA EN RED (CIBER), INSTITUCIO CATALANA DE RECERCA TESTUDIS AVANCATS
    Inventors: Aurora Pujol Onofre, Erwin Knecht Roberto
  • SPECIFIC MTOR INHIBITORS IN THE TREATMENT OF X-LINKED ADRENOLEUKODYSTROPHY
    Publication number: 20170273915
    Abstract: The invention relates to novel uses of specific mTOR inhibitors as a medicament, in particular for the treatment of X-linked adrenoleukodystrophy (X-ALD). The invention also relates to a method for identifying a compound potentially useful for the treatment and/or prevention of X-ALD.
    Type: Application
    Filed: September 21, 2015
    Publication date: September 28, 2017
    Inventors: Aurora PUJOL ONOFRE, Erwin KNECHT ROBERTO
  • Pioglitazone for use in the treatment of adrenoleukodystrophy
    Patent number: 8865747
    Abstract: The present invention is directed to pioglitazone, or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition comprising pioglitazone, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in the treatment and/or prevention of an adrenoleukodystrophy.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 21, 2014
    Assignees: Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL), Fundació Institució Catalana de Recerca I Estudis Avançats (ICREA), Fondation ELA
    Inventor: Aurora Pujol Onofre
  • PIOGLITAZONE FOR USE IN THE TREATMENT OF ADRENOLEUKODYSTROPHY
    Publication number: 20130274295
    Abstract: The present invention is directed to pioglitazone, or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition comprising pioglitazone, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in the treatment and/or prevention of an adrenoleukodystrophy.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 17, 2013
    Inventor: Aurora PUJOL ONOFRE